J C Furlan1, M D I Vergouwen, J Fang, F L Silver. 1. Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Department of Genetics and Development, Toronto Western Research Institute, Toronto, ON, Canada; Lyndhurst Centre, Toronto Rehabilitation Institute, Toronto, ON, Canada.
Abstract
BACKGROUND AND PURPOSE: In patients with ischaemic stroke, elevated white blood cell count (WBC) has been associated with stroke severity on admission and poor functional outcome. However, previous studies did not control for confounding factors. We hypothesized that higher WBC is an independent predictor of stroke severity, greater degree of disability and 30-day mortality after acute ischaemic stroke. METHODS: Data from the Registry of the Canadian Stroke Network on consecutive patients with acute ischaemic stroke admitted between July 2003 and March 2008 were used. Patients were divided into groups as follows: low WBC (0.1-4 × 10(-9) /l), normal WBC (4.1-10 × 10(-9) /l) and high WBC (10.1-40 × 10(-9) /l). Primary outcome measures were the frequency of moderate/severe strokes on admission (Canadian Neurological Scale ≤ 8), greater degree of disability at discharge (modified Rankin score 3-6) and 30-day mortality. Regression analyses were performed adjusting for confounders. RESULTS: In total, 8829 patients were included. After adjustment for major potential confounders, every 1 × 10(-9) /l increase in WBC was associated with stroke severity on admission [odds ratio (OR) 1.09; 95%CI 1.07-1.10; P < 0.0001), disability at discharge (OR 1.04; 95%CI 1.02-1.06; P = 0.0005) and 30-day mortality (hazard ratio 1.07; 95%CI 1.05-1.08; P < 0.0001). The Kaplan-Meier curves indicate that elevated WBC is associated with higher mortality after acute ischaemic stroke (P = 0.001). CONCLUSIONS: In patients with acute ischaemic stroke, higher WBC on admission is an independent predictor of stroke severity on admission, greater degree of disability at discharge and 30-day mortality. These results reinforce the need for further studies focused on immunomodulation therapy targeting inflammatory response following acute ischaemic stroke.
BACKGROUND AND PURPOSE: In patients with ischaemic stroke, elevated white blood cell count (WBC) has been associated with stroke severity on admission and poor functional outcome. However, previous studies did not control for confounding factors. We hypothesized that higher WBC is an independent predictor of stroke severity, greater degree of disability and 30-day mortality after acute ischaemic stroke. METHODS: Data from the Registry of the Canadian Stroke Network on consecutive patients with acute ischaemic stroke admitted between July 2003 and March 2008 were used. Patients were divided into groups as follows: low WBC (0.1-4 × 10(-9) /l), normal WBC (4.1-10 × 10(-9) /l) and high WBC (10.1-40 × 10(-9) /l). Primary outcome measures were the frequency of moderate/severe strokes on admission (Canadian Neurological Scale ≤ 8), greater degree of disability at discharge (modified Rankin score 3-6) and 30-day mortality. Regression analyses were performed adjusting for confounders. RESULTS: In total, 8829 patients were included. After adjustment for major potential confounders, every 1 × 10(-9) /l increase in WBC was associated with stroke severity on admission [odds ratio (OR) 1.09; 95%CI 1.07-1.10; P < 0.0001), disability at discharge (OR 1.04; 95%CI 1.02-1.06; P = 0.0005) and 30-day mortality (hazard ratio 1.07; 95%CI 1.05-1.08; P < 0.0001). The Kaplan-Meier curves indicate that elevated WBC is associated with higher mortality after acute ischaemic stroke (P = 0.001). CONCLUSIONS: In patients with acute ischaemic stroke, higher WBC on admission is an independent predictor of stroke severity on admission, greater degree of disability at discharge and 30-day mortality. These results reinforce the need for further studies focused on immunomodulation therapy targeting inflammatory response following acute ischaemic stroke.
Authors: Ana I Casas; Pamela Wm Kleikers; Eva Geuss; Friederike Langhauser; Thure Adler; Dirk H Busch; Valerie Gailus-Durner; Martin Hrabê de Angelis; Javier Egea; Manuela G Lopez; Christoph Kleinschnitz; Harald Hhw Schmidt Journal: J Clin Invest Date: 2019-03-18 Impact factor: 14.808
Authors: Edward R Bader; Tiberiu A Pana; Raphae S Barlas; Anthony K Metcalf; John F Potter; Phyo K Myint Journal: J Neurol Date: 2022-07-22 Impact factor: 6.682
Authors: Ewgenia Barow; Fanny Quandt; Bastian Cheng; Mathias Gelderblom; Märit Jensen; Alina Königsberg; Florent Boutitie; Norbert Nighoghossian; Martin Ebinger; Matthias Endres; Jochen B Fiebach; Vincent Thijs; Robin Lemmens; Keith W Muir; Salvador Pedraza; Claus Z Simonsen; Christian Gerloff; Götz Thomalla Journal: Front Neurol Date: 2022-06-13 Impact factor: 4.086
Authors: Anna-Sophia Wahl; Eva Erlebach; Biagio Brattoli; Uta Büchler; Julia Kaiser; Benjamin V Ineichen; Alice C Mosberger; Shirin Schneeberger; Stefan Imobersteg; Martin Wieckhorst; Martina Stirn; Aileen Schroeter; Bjoern Ommer; Martin E Schwab Journal: J Cereb Blood Flow Metab Date: 2018-05-17 Impact factor: 6.200
Authors: Natalia S Rost; James F Meschia; Rebecca Gottesman; Lisa Wruck; Karl Helmer; Steven M Greenberg Journal: Stroke Date: 2021-05-27 Impact factor: 10.170